How are erythropoietic-stimulating agents (ESA) most helpful for patients with chronic kidney disease? What target levels of iron should clinicians maintain before starting ESA therapy, and what challenges will we encounter in this process? Host Dr. Charles Turck probes these questions and more with Dr. Sarah Tomasello, clinical associate professor at the Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey, and a clinical specialist in nephrology at Robert Wood Johnson University Hospital in New Jersey.